The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment

Background/aim: SARS-CoV-2, a ribonucleic acid coronavirus, rapidly spread worldwide within short timeframe. Although different antiviral, antiinflammatory, and immunomodulatory drugs are used, current evidence is insufficient as to which drug more efficient. Our study compared favipiravir lopinavir/ritonavir (LPV/RTV) therapies in inpatient care for coronavirus disease 2019 (COVID-19) pneumonia. Materials methods: Demographic data, test results, treatments, latest status of patients receiving COVID-19 pneumonia therapy were recorded. The initial LPV/RTV groups regarding the need intensive units (ICU) mortality. Logistic regression analysis was performed by including variables showing significant differences result paired comparisons into model. Results: Of 204 with pneumonia, 59 (28.9%), 131 (64.2%), 14 administered LPV/RTV, favipiravir, respectively. No difference found age, sex, presence comorbidity, tocilizumab, systemic corticosteroid, plasma use between these three treatment regimens. mean mortality age 71 ± 14.3 years, substantially greater than that survivors (54.2 15.5 years). Compared ICU admission rates lower favipiravir. CK-MB, AST, CRP, LDH, creatinine levels higher, whereas lymphocyte counts who died. Age, neutrophil higher needing ICU, eosinophil significantly lower. showed independently decreased (p = 0.006). Conclusion: effective reducing hospitalized COVID-19.